ImmunityBio, Inc.
NASDAQ:IBRX
2.76 (USD) • At close January 6, 2025
Overzicht | Financiële gegevens
Bedrijfsnaam | ImmunityBio, Inc. |
Symbool | IBRX |
Munteenheid | USD |
Prijs | 2.76 |
Beurswaarde | 2,015,255,400 |
Dividendpercentage | 0% |
52-weken bereik | 2.5 - 10.53 |
Industrie | Biotechnology |
Sector | Healthcare |
CEO | Mr. Richard Gerald Adcock |
Website | https://immunitybio.com |
An error occurred while fetching data.
Over ImmunityBio, Inc.
ImmunityBio, Inc., a clinical-stage biotechnology company, develops therapies and vaccines to treat cancers and infectious diseases. It offers immunotherapy and cell therapy platforms, including antibody cytokine fusion proteins, synthetic immunomodulators, vaccine technologies, natural killer cells, and adaptive (T cell) immune systems. The company also develops therapeutic agents, which are in
Vergelijkbare Aandelen
Financiële Gegevens
Cijfers zijn in miljoenen (USD)
Cijfers zijn in miljoenen (USD)